Andersson JK, Mucelli RP, Epstein E, et al. - In women with diffuse adenomyosis, significant reduction in heavy menstrual bleeding and pain is achieved with vaginal bromocriptine. Researchers conducted a pilot study examining the influence of bromocriptine treatment on imaging findings of adenomyosis, as assessed by transvaginal ultrasound (TVU) and magnetic resonance imaging (MRI). Treatment with vaginal bromocriptine for 6 months was provided to 18 women (aged 35-50 ) with heavy menstrual bleeding and diffuse adenomyosis according to both MRI and TVU. Among these patients, Pictorial Blood Loss Assessment Chart (PBLAC) scores were > 250 and 66.7% reported moderate to severe pain during menstruation at baseline. In TVU, a significant reduction in maximal Junctional Zone (JZmax) was observed; in addition, there was a reduction in the number of women with asymmetric myometrial wall thickness. The changes seen in this small pilot study may indicate that radiological appearance reflects the impacts of vaginal bromocriptine on adenomyosis.